STATEMENT Ottawa, October 23, 2020 – Innovative Medicines Canada (IMC) issued the following statement today in response to the release of PMPRB’s final Guidelines: “For the last five years we have […]
STATEMENT Ottawa, September 25, 2020 – The following statement can be attributed to Declan Hamill, Vice President, Legal, Regulatory Affairs & Compliance, Innovative Medicines Canada in response to the Trump […]
A comprehensive review of the existing body of research demonstrates that there is greater evidence of a decline […]
Ottawa, August 12, 2020 – This fall’s federal budget will be critical in supporting Canada’s economic and social recovery. Not only will it offer an opportunity for the federal government […]
Dr. Doron Sagman is Lilly Canada’s Vice President of R&D and Medical Affairs as well as Lilly’s Senior Medical Director. Doron is a physician with nearly 20 years of experience […]
Second PMPRB consultation on new drug pricing rules will tackle drug access […]
Dr. Alex Romanovschi is GSK Canada’s Country Medical Director. Alex is a physician with nearly 20 years of experience in the pharmaceutical industry spanning many therapeutic areas, including cardiovascular diseases, […]
Innovative Medicines Canada’s (IMC) members are contributing to the fight against COVID-19 in a variety of ways. While many of our member companies are researching potential vaccines and treatments for […]
Vatche is the President and Founder of Vantage BioTrials, a Canadian CRO specialized in clinical trial management services. He’s contributed his strong drug development knowledge to the pharma and clinical […]
Dion Neame is the Country Medical Lead for Sanofi Canada and Country Medical Head for Pasteur, the vaccine arm of Sanofi. He is also a pediatrician working in Pediatric Urgent […]
